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Downregulation of sphingosine 1-phosphate 
(S1P) receptor 1 by dexamethasone inhibits S1P-
induced mesangial cell migration
Abstract: Sphingosine 1-phosphate (S1P) is generated by 
sphingosine kinase (SK)-1 and -2 and acts mainly as an 
extracellular ligand at five specific receptors, denoted 
S1P1−5. After activation, S1P receptors regulate impor-
tant processes in the progression of renal diseases, such 
as mesangial cell migration and survival. Previously, we 
showed that dexamethasone enhances SK-1 activity and 
S1P formation, which protected mesangial cells from 
stress-induced apoptosis. Here we demonstrate that dex-
amethasone treatment lowered S1P1 mRNA and protein 
expression levels in rat mesangial cells. This effect was 
abolished in the presence of the glucocorticoid receptor 
antagonist RU-486. In addition, in vivo studies showed 
that dexamethasone downregulated S1P1 expression in 
glomeruli isolated from mice treated with dexamethasone 
(10 mg/kg body weight). Functionally, we identified S1P1 
as a key player mediating S1P-induced mesangial cell 
migration. We show that dexamethasone treatment sig-
nificantly lowered S1P-induced migration of mesangial 
cells, which was again reversed in the presence of RU-486. 
In summary, we suggest that dexamethasone inhibits S1P-
induced mesangial cell migration via downregulation of 
S1P1. Overall, these results demonstrate that dexametha-
sone has functional important effects on sphingolipid 
metabolism and action in renal mesangial cells.
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Introduction
Sphingosine 1-phosphate (S1P) is known to influence 
pathophysiologically important processes involved in the 
progression of numerous renal diseases (for review, see 
Koch et al., 2013a). S1P is generated via the activity of two 
different kinase subtypes, sphingosine kinase (SK)-1 and -2. 
Once generated, S1P can act either intracellularly via 
recently identified targets or most commonly via activation 
of five specific receptors on the cell surface, denoted as 
S1P1−5 (for review, see Sanchez and Hla, 2004; Strub et al., 
2010). After activation S1P receptors regulate mesangial 
cell migration and proliferation, cell survival and the for-
mation of extracellular matrix components, which are all 
important steps in the pathogenesis of renal diseases (for 
review, see Koch et al., 2013a). The five known S1P recep-
tors couple to and activate a variety of different G proteins, 
namely Gi (S1P1−5), Gq (S1P2/3), and G12/13 (S1P2−5) and are 
characterized by a cell-type-specific expression pattern 
(for review, see Sanchez and Hla, 2004). Thus, depend-
ing on the cell type and binding to a specific G  protein, 
activation of distinct S1P receptors may result in diverse 
functional outcomes. In this regard, it is generally known 
that activation of S1P1 and S1P3 triggers cell migration, 
whereas S1P2 is linked to anti-migratory effects (for review, 
see Sanchez and Hla, 2004). In renal mesangial cells, 
which mainly express S1P1−3 and S1P5 (Katsuma et  al., 
2002; Koch et al., 2013b), it was demonstrated previously 
that exogenous S1P stimulates cell migration ( Klawitter 
et al., 2007). However, in contrast to the reported inhibi-
tory effect of S1P2 activation in various other cell types (for 
review, see Sanchez and Hla, 2004), we recently suggested 
a pro-migratory role of S1P2 for S1P-induced mesangial 
cell migration (Völzke et al., 2014). We demonstrated that 
exogenous S1P enhanced the activity of cyclooxygenase 2 
(COX-2) and subsequently the formation of prostaglandin 
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E2 (PGE2), which was abolished in the presence of the S1P2 
antagonist JTE-013 and specific siRNA against this recep-
tor subtype. Interestingly, pharmacological inhibition of 
COX-2 blocked the S1P-stimulated migratory response, 
suggesting that extracellular S1P triggers mesangial cell 
migration partially via the activation of the S1P2/COX-2 sign-
aling pathway (Völzke et al., 2014). Most notably, we also 
pointed out that the additional activation of S1P1 and S1P3 
by S1P apparently contributes to the migratory response of 
mesangial cells without requiring COX-2 induction (Völzke 
et al., 2014). Taken together, these data demonstrate that 
extracellular S1P via activation of S1P1−3 triggers the migra-
tion of renal mesangial cells, which might be involved in 
the progression of renal diseases. In general, modulating 
sphingolipid pathways could be an attractive target for 
new treatment strategies and, moreover, might explain the 
known beneficial effects of classical renal protective drugs. 
In this context, we recently showed that glucocorticoids, 
e.g., dexamethasone, which are commonly used for the 
treatment of chronic inflammatory kidney diseases, have a 
protective effect on stress-induced apoptosis of glomerular 
mesangial cells (Förster et al., 2010). The authors demon-
strated that this action involves activation of the sphingo-
myelin signaling module accompanied by a coordinated 
expression and stimulation of neutral ceramidase and SK-1 
activities, which in turn result in increased cellular S1P 
levels and protection from staurosporine-induced apop-
tosis. These results may explain why glucocorticoids have 
been used successfully to treat numerous clinical condi-
tions affecting the kidney, and provide strong evidence 
that the renoprotective actions can be partially explained 
by targeting SK-1 and S1P metabolism in resident glomeru-
lar cells.
However, so far nothing is known about the effect of 
glucocorticoids on S1P receptor expression and function 
in glomerular cells. In this study we investigated whether 
dexamethasone alters S1P receptor expression pattern in 
renal mesangial cells and in mouse glomeruli and whether 
this impacts on S1P-induced mesangial cell migration.
Results
Dexamethasone downregulates S1P1 
 expression in renal mesangial cells
First, we evaluated whether dexamethasone treatment 
alters the S1P receptor expression in renal mesangial 
cells. We treated rat mesangial cells for 24 h with increas-
ing concentrations of dexamethasone (1–300 nm) and 
Table 1: Effect of dexamethasone on the mRNA expression levels of 
S1P receptors in rat mesangial cells.
S1P 
receptor 
subtype
DEX (nm)
0 1 10 100 300
S1P1 100±0 50.4±4.60a 27.7±7.76a 21.8±3.10a 17.1±3.10a
S1P2 100±0 77.9±14.2 70.4±7.02 72.6±16.8 83.7±15.6
S1P3 100±0 73.0±6.87 71.4±16.9 47.2±8.34b 50.6±12.2b
S1P5 100±0 102±25.2 106±38.8 131±15.3 123±22.6
S1P1, S1P2, S1P3, and S1P5 mRNA expression levels were determined by 
TaqMan® analysis after 24 h of treatment with the indicated concentra-
tions of dexamethasone (DEX). Results are expressed as mean±SEM. 
(n = 5); ap<0.001, bp < 0.05, compared to the respective controls.
measured the mRNA expression levels using TaqMan® 
analysis. As shown in Table 1, S1P1 mRNA expression 
levels were significantly downregulated by this treatment. 
We also investigated whether dexamethasone treatment 
altered the expression of other S1P receptors in renal 
mesangial cells. The mRNA expression levels of S1P2 and 
S1P5 were not significantly altered after the treatment with 
increasing concentrations of dexamethasone (Table 1). 
The mRNA expression level of S1P4, which is normally not 
expressed in renal mesangial cells (Katsuma et al., 2002; 
Koch et al., 2013b), was also not affected upon stimulation 
with 1–300 nm dexamethasone for 24 h (data not shown). 
However, the S1P3 mRNA expression was significantly 
downregulated after stimulation with 100 and 300 nm 
dexamethasone (Table 1), whereas the protein expression 
of S1P3 upon stimulation with dexamethasone for 24 h was 
not altered (Figure 1E).
To further evaluate the effect of dexamethasone 
on S1P1 expression, we treated rat mesangial cells with 
100 nm dexamethasone for different time periods (2–24 h). 
As shown in Figure 1A, stimulation with dexamethasone 
led to a strong downregulation of S1P1 mRNA expression 
at all of the time points investigated compared to the 
respective controls. Moreover, 4 and 24 h treatment of rat 
mesangial cells with 100 nm dexamethasone significantly 
downregulated S1P1 mRNA (Figure 1B) as well as protein 
expression (Figure 1C). To verify whether dexamethasone 
alters S1P1 expression directly via activation of the glu-
cocorticoid receptor (GR), we stimulated rat mesangial 
cells in parallel with 1 μm of the GR antagonist RU-486 
(Jung-Testas and Baulieu, 1983). Figures 1B and C clearly 
show that the reduction of S1P1 mRNA and protein expres-
sion upon treatment with 100 nm dexamethasone was 
diminished in the presence of 1 μm RU-486. Stimulation 
of rat mesangial cells with 1 μm RU-486 alone for either 
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Figure 1: Dexamethasone downregulates S1P1 expression in rat mesangial cells.
(A) S1P1 mRNA expression levels after treatment with 100 nm dexamethasone (DEX) for the indicated time points. (B) S1P1 mRNA expression 
levels after 4 h and 24 h of treatment with 100 nm DEX and 1 μm RU-486. (A,B) S1P1 mRNA expression levels (gray bars) were determined by 
TaqMan® analysis and are shown relative to control cells (vehicle alone, white bars). (C) S1P1 protein expression levels after 4 h and 24 h 
of treatment with 100 nm DEX and 1 μm RU-486 were determined by Western blot analysis. Bands corresponding to S1P1 and β-actin were 
densitometrically evaluated and are shown relative to control cells (vehicle alone; white bars; for representative Western blot, see upper 
panels). (D) S1P1 mRNA expression levels after 4 h and 24 h treatment with 100 nm dexamethasone (DEX), betamethasone (BET), hydrocor-
tisone (HYD), and aldosterone (ALD). S1P1 mRNA expression levels (gray bars) were determined by TaqMan® analysis and are shown relative 
to control cells (vehicle alone, white bars). (E) Representative Western blot of S1P3 protein expression levels after 24 h treatment with 
100 nm DEX and 1 μm RU-486. All results are expressed as mean±SEM (n = 3-5). *p < 0.05, **p < 0.01, ***p < 0.001, compared to the respective 
controls. #p < 0.05, ##p < 0.01, ###p < 0.001, compared to dexamethasone-treated cells.
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4 or 24  h did not significantly influence the S1P1 mRNA 
expression [4 h, control (vehicle alone) = 100±0, RU-486 
(1 μm) = 86.9±11.7; 24 h, control (vehicle alone) = 100±0, 
RU-486 (1 μm) = 79.2±9.77; mean±SEM; n = 3]. Furthermore, 
other glucocorticoids (betamethasone, hydrocortisone) 
and the mineralocorticoid aldosterone, which is also able 
to bind to the GR, downregulated S1P1 mRNA expression 
(Figure 1D), overall indicating that the downregulation of 
S1P1 is mediated by the GR.
Finally, we investigated whether the dexamethasone-
mediated reduction of S1P1 expression is also occurring in 
other species as well as in vivo. Therefore, we first treated 
isolated mouse mesangial cells with increasing concentra-
tions of dexamethasone (10–300 nm) for 24 h and meas-
ured the S1P1 mRNA expression levels compared to the 
vehicle-treated controls. As illustrated in Figure 2A, S1P1 
mRNA expression was significantly downregulated upon 
stimulation with 10–300 nm dexamethasone. In addition, 
we treated male C57BL/6 mice with 10 mg/kg body weight 
dexamethasone (intraperitoneal injection) for 24  h and 
analyzed the mRNA expression of S1P1 in subsequently iso-
lated kidney glomeruli. As seen in Figure 2B, S1P1 mRNA 
expression was significantly reduced in dexamethasone-
treated mice compared to the vehicle-treated control group.
Downregulation of S1P1 by dexametha-
sone inhibits S1P-induced mesangial cell 
migration
In principle, activation of distinct S1P receptor subtypes 
by S1P is well known to induce cell migration of various 
cell types (for review, see Sanchez and Hla, 2004). In renal 
mesangial cells, we could previously demonstrate that 
inhibition of COX-2, which is up-regulated by S1P2, blocked 
S1P-induced migration (Völzke et  al., 2014). In addition, 
the inhibitor of S1P1 and S1P3, VPC-23019, also diminished 
S1P-induced cell migration (Völzke et  al., 2014), overall 
indicating that all three S1P receptor subtypes, S1P1−3, play 
a crucial role for S1P-induced mesangial cell migration. 
Here, we further evaluated the pro-migratory effect of S1P1 
and investigated whether downregulation of this receptor 
subtype by dexamethasone influences S1P-induced renal 
mesangial cell migration. As illustrated in Figure 3A, treat-
ment with 1 μm S1P clearly induced migration, which was 
significantly reduced in the presence of the S1P1 antago-
nist W146 (Sanna et al., 2006). Moreover, 4 h stimulation 
with the S1P1 agonist SEW2871 (Sanna et al., 2004) induced 
mesangial cells migration in a concentration dependent 
manner (Figure 3B). To further evaluate the pro-migratory 
role of S1P1 independent of S1P2- and COX-2-mediated 
effects, we stimulated cells with p-FTY720, which binds 
to all S1P receptors, except S1P2 (Brinkmann et al., 2002) 
and does not induce COX-2 protein expression in mesan-
gial cells (Völzke et al., 2014). As shown in Figure 4, treat-
ment with 1 μm p-FTY720 for 4 h induced mesangial cell 
migration. This effect was significantly reduced after 
pretreatment with either 1 μm W146 (Figure 4A) or 10 μm 
VPC-32019 (an antagonist at S1P1/3 (Davis et  al., 2005); 
Figure 4B). In contrast, pretreatment with the COX-2 inhib-
itor SC-236 did not affect p-FTY720-dependent induction 
of mesangial cells migration (Figure 4C). Overall, these 
data strongly suggest that the induction of mesangial cell 
migration by pFTY-720 is mediated by activation of S1P1, 
which further demonstrate the pro-migratory role of this 
receptor subtype in renal mesangial cells.
Figure 2: Dexamethasone downregulates S1P1 expression in mouse mesangial cells and isolated mouse glomeruli.
(A) S1P1 mRNA expression levels after 24 h treatment with the indicated concentrations of dexamethasone (DEX). (B) S1P1 mRNA expression 
levels after intraperitoneally injection of 10 mg/kg body weight dexamethasone (DEX) in mice. After 24 h, kidneys were harvested and taken 
for isolation of glomeruli by using a differential sieving method. All S1P1 mRNA expression levels (gray bars) were determined by TaqMan® 
analysis and are shown relative to control cells (vehicle alone, white bars). (A) Results are expressed as mean±SEM (n = 4). (B) Results are 
expressed as mean±S.D. (n = 5). *p < 0.05, **p < 0.01, ***p < 0.001, compared to the respective controls.
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 4/29/19 3:45 PM
A. Koch et al.: Dexamethasone decreases S1P1 and S1P-induced migration      807
Next, we evaluated whether downregulation of S1P1 
by dexamethasone alters S1P and p-FTY720 dependent 
induction of mesangial cell migration. As illustrated in 
Figure 5A, parallel treatment for 4  h with 100 nm dexa-
methasone significantly inhibited S1P-induced mesan-
gial cell migration. Moreover, migration induced by 24 h 
treatment with 1 μm S1P was completely abolished in the 
presence of 100 nm dexamethasone (Figure 5B). In addi-
tion, parallel stimulation for 4 h with 100 nm dexametha-
sone inhibited p-FTY720-induced migration (Figure  5C), 
whereas stimulation with 1 μm p-FTY720 for 24  h did 
not induce mesangial cell migration at all (Figure 5D). In 
contrast, we detected no significant effect on mesangial 
cell migration after incubation with 100 nm dexametha-
sone alone for either 4 h [control (vehicle alone) = 100±0, 
DEX (100 nm) = 83.4±7.30; mean±SEM; n = 3] or 24  h 
[control (vehicle alone) = 100±0, DEX (100 nm) = 84.5±5.30; 
mean±SEM; n = 4]. Most notably, the inhibitory effect of 
dexamethasone on S1P-induced migration was signifi-
cantly reversed in the presence of the GR inhibitor RU-486 
(Figure 5A, B).
Discussion
Glucocorticoids are commonly used to treat inflammatory 
renal diseases and their beneficial properties have been 
evaluated in various experimental settings (Kumar et al., 
2009; Moysiadis et  al., 2012). Our results provide strong 
Figure 3: S1P1 plays a crucial role for S1P-induced rat mesangial cell migration.
(A) Migration after 1 h pretreatment with 1 μm W146 and additional 4 h of treatment with 1 μm S1P. (B) Migration after 4 h of treatment with 
the indicated concentrations of SEW2871. Mesangial cell migration was measured by Boyden chamber assays. Results are shown relative 
to control cells (vehicle alone, white bars). All values are mean±SEM (n = 3-4). *p < 0.05, **p < 0.01, ***p < 0.001, compared to the respective 
controls. ##p < 0.01, compared to the S1P-treated cells.
Figure 4: S1P1 plays a crucial role for p-FTY720-induced rat mesangial cell migration.
(A–C) Migration after 1 h pretreatment with either (A) 1 μm W146, (B) 10 μm VPC-23019, or (C) 10 μm SC-236, and additional 4 h treatment 
with 1 μm p-FTY720. Mesangial cell migration was measured by Boyden chamber assays. Results are shown relative to control cells (vehicle 
alone, white bars). All values are mean±SEM (n = 3-4). **p < 0.01, ***p < 0.001, compared to the respective controls. ###p < 0.001, compared 
to the S1P-treated cells (n.s. = not significant).
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Figure 5: Dexamethasone downregulates S1P-induced rat 
 mesangial cell migration.
(A,B) Migration after 4 h (A) and 24 h (B) treatment with 1 μm S1P in 
parallel with 100 nm dexamethasone (DEX) and 1 μm RU-486.  
(C) Migration after 4 h of treatment with 1 μm p-FTY720 and 100 nm 
dexamethasone (DEX). Mesangial cell migration was measured 
by Boyden chamber assays. Results are shown relative to control 
cells (vehicle alone, white bars). All values are mean±SEM (n = 3-4). 
***p < 0.001, compared to the respective controls. ##p < 0.05, 
###p < 0.001, compared to the S1P-treated cells. §p < 0.05, compared 
to the S1P/DEX-treated cells.
evidence that part of the renal protective actions of glu-
cocorticoids can be explained by targeting SK-1, S1P1 and 
S1P receptor metabolism in resident glomerular cells. 
Förster et  al. (2010) demonstrated that dexamethasone 
alters sphingolipid metabolism by upregulation of neutral 
ceramidase and SK-1 expression and activity and by this 
protects mesangial cells from stress-induced apoptosis 
via enhanced formation of intracellular S1P. In addition, 
we demonstrate here for the first time that dexametha-
sone markedly reduced the expression of S1P1 in isolated 
mesangial cells and mouse glomeruli, which lead to lower 
S1P-induced mesangial cell migration. In this regard, it is 
still not clear when in the course of renal diseases mesan-
gial cell migration occurs in vivo and how this contributes 
to the disease conditions. It is tempting to speculate that 
enhanced migration of mesangial cells could be ben-
eficial, e.g., by counteracting initial mesangial cell lysis 
during forms of mesangioproliferative glomerulonephritis 
and contribute to resolution of disease. Definitely, further 
studies are required to address the role of mesangial cell 
migration in vivo in more detail.
The molecular mechanisms by which dexamethasone 
alters S1P1 expression levels are not known so far. Typically, 
glucocorticoids act via activation of GR, which is expressed 
in renal mesangial cells (Förster et  al., 2010) and subse-
quent binding and activation of specific response elements, 
so-called GREs, in the promoter of target genes. Förster 
et al. (2010) demonstrated that upregulation of neutral cer-
amidase by dexamethasone is directly regulated via func-
tional GREs. However, downregulation of gene expression 
by dexamethasone treatment, as we demonstrated here for 
S1P1, could be the result of either direct binding to putative 
negative GREs or by transrepression involving the interac-
tion between GR and a range of transcription factors like 
activator protein-1 or nuclear  factor-κB (for review, see De 
Bosscher et al., 2003). Whether one of these mechanisms 
is responsible for the reported downregulation of S1P1 
expression upon dexamethasone treatment needs to be 
investigated in future studies.
In this regard, it is tempting to speculate whether 
dexamethasone-dependent SK-1 upregulation may have 
an impact on S1P1 expression. Data by Meyer zu Hering-
dorf et al. (2001) showed that activation of S1P receptors 
enhance SK-1 activity in human embryonic kidney cells 
(HEK293). Most interestingly, these authors speculated 
that HEK293 cells may respond to SK-1 upregulation and 
activation by either an up- or downregulation of distinct 
S1P receptor subtypes. Whether this could explain the 
reduced S1P1 expression upon dexamethasone stimula-
tion in renal mesangial cells is not yet proven. However, 
we previously reported that both, glitazones (rosiglitazone 
and troglitazone) and dexamethasone indeed enhance 
the expression and activity of SK-1 (Förster et  al., 2010; 
Koch et al., 2012), but still have opposite effects on S1P1 
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mRNA and protein expression (Figure 1; Koch et al., 2013b) 
indicating that SK-1 activation does not directly influence 
S1P1 expression in renal mesangial cells. Interestingly, 
S1P3 mRNA expression was significantly decreased upon 
dexamethasone treatment, whereas the protein expres-
sion was not altered (Table 1 and Figure 1E). Obviously, 
in rat mesangial cells S1P3 expression seems to be regu-
lated not only on the transcriptional level, but also on a 
posttranscriptional level by altering mRNA stability and/
or translational effects, which should be investigated in 
further studies.
Functionally, we clearly show that S1P1 plays an 
essential role mediating the S1P-induced migration of 
renal mesangial cells and that dexamethasone inhibits 
the migratory response by downregulation of this recep-
tor subtype. In principle, S1P1 and S1P3 are well known 
to trigger migration of various cell types (for review, see 
Sanchez and Hla, 2004). In renal mesangial cells we 
additionally demonstrated that activation of COX-2 and 
enhanced formation of PGE2 via S1P2 triggers S1P-induced 
cell migration (Völzke et  al., 2014). In parallel, our own 
data using several agonists and antagonists for S1P1 show 
that this receptor subtype also plays a crucial role for S1P-
induced mesangial cell migration. First of all, the dual 
S1P1/3 antagonist VPC-23019 (Davis et  al., 2005) dimin-
ished S1P- and pFTY720-induced mesangial cell migration 
(Völzke et al., 2014, Figure 4B). Further, SEW2871 signifi-
cantly enhanced mesangial cell migration. As shown in 
Figure 3B, we detected enhanced migration of rat mesan-
gial cells after stimulation with concentration above 
1 μm with significant effects at 5 and 10 μm SEW2871. 
Sanna et  al. (2004) established SEW2871 as a selective 
S1P1 agonist with no effect on S1P2−5 at concentrations up 
to 10 μm. Therefore and also considering that VPC-23019 
inhibited S1P- as well as p-FTY720-induced migration, we 
think that the pro-migratory effect of SEW2871 is due to 
S1P1 activation. However, we cannot fully exclude, that the 
effect of 5 and 10 μm SEW2871 on mesangial cell migra-
tion could be mediated via activation of other receptors 
independently of S1P receptors. In this regard, it is tempt-
ing to speculate that also high concentrations of W146 
may act quite unspecific. This might explain the fact that 
W146 blocked S1P-induced migration almost completely 
(Figure 3A), which in a way contrasts to our previous find-
ings about the role of S1P2-mediated COX-2 activation and 
subsequently induced mesangial cell migration (Völzke 
et al., 2014). Overall, we suggest that both, COX-2-depend-
ent (via S1P2) and independent (via S1P1) mechanisms are 
involved in the migratory response of renal mesangial 
cells upon S1P treatment. This hypothesis should be veri-
fied by genetic approaches in future studies.
To investigate effects without affecting S1P2 we used 
p-FTY720, which is known to activate all S1P receptors 
except S1P2 (Brinkmann et al., 2002) and does not induce 
COX-2 expression (Völzke et al., 2014). Interestingly, stim-
ulation with p-FTY720 for 4 h clearly induced mesangial 
cell migration. This effect is blocked by pretreatment with 
W146 and VPC-23019 (Figure 4A and B), which further 
underlines the role of S1P1 for mesangial cell migration. 
In principle, FTY720 (fingolimod) and its phosphorylated 
form are known to act as ‘functional antagonists’ at S1P1 
(for review, see Brinkmann et al., 2010). After initial recep-
tor activation, which is responsible for the induction of 
mesangial cell migration upon short time stimulation with 
p-FTY720, fingolimod causes S1P1 to internalize from cell 
membranes resulting in receptor degradation and inhi-
bition of cell migration. In this context, the current data 
raise the interesting question of whether dexamethasone 
mimics the effect of fingolimod on lymphocyte trafficking 
via transcriptional downregulation of pro-migratory S1P1, 
and if so, whether this effect contributes to the known 
anti-inflammatory properties of glucocorticoids. Beside 
the well established role of S1P receptors for the mediation 
of migratory cell responses, our previous findings sug-
gested that also SK-1 activation is crucial for the migration 
of cells (Döll et al., 2007; Klawitter et al., 2007). Döll et al. 
(2007) showed that SK-1 is critically involved in the migra-
tion of the breast adenocarcinoma cell line MCF7 stimu-
lated by prolactine. In renal mesangial cells it was shown 
that downregulation of SK-1 by siRNA transfection abro-
gated the migratory response induced by S1P (Klawitter 
et al., 2007), suggesting that SK-1 is obviously required for 
S1P-induced migration. Thus, upregulation of SK-1 activity 
and intracellular formation of S1P by dexamethasone as 
it was shown by Förster et al. (2010) is supposed to lead 
to higher mesangial cell migration. Our present data now 
demonstrate that dexamethasone inhibits S1P-induced 
migration via reduced expression of S1P1. Obviously, the 
downregulation of S1P1 overrides the fostering role of SK-1 
on S1P-induced mesangial cell migration upon exposure 
to dexamethasone. Moreover, it is tempting to speculate 
that dexamethasone also affects putative S1P transporters 
and thereby alters the intra- and extracellular S1P concen-
trations and the activation status of the participating S1P 
receptors. In this regard, Nieuwenhuis et al. (2009) dem-
onstrated that dexamethasone upregulates Abcc1 expres-
sion in human fibroblasts, which is one of the putative 
S1P transporters believed to be involved in shuttling S1P 
across membranes (Mitra et al., 2006). In contrast to our 
findings, these authors did not see any changes in S1P1 
expression (Nieuwenhuis et  al., 2009). Whether dexa-
methasone alters the expression and activity of putative 
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S1P transporters, such as Abcc1 or spinster-2, in renal 
mesangial cells and if this in turn complements the cross-
talk between the migratory response of SK-1 activation and 
S1P formation and reduced expression of pro-migratory 
S1P1 after dexamethasone stimulation needs to be clari-
fied in future studies.
Taken together, we demonstrate that dexamethasone 
inhibits S1P-induced mesangial cell migration via down-
regulation of pro-migratory S1P1. Obviously, dexametha-
sone has a variety of functional important effects on SK-1 
and S1P1 signaling pathways, in renal mesangial cells, 
which probably form part of the known renal protective 
effects of glucocorticoids.
Materials and methods
Chemicals
Dexamethasone, betamethasone, hydrocortisone, aldosterone and 
RU-486 were from Sigma-Aldrich (Steinheim, Germany). S1P, phos-
pho-FTY720 (p-FTY720), and SEW2871 were obtained from Cayman 
Chemicals (Ann Arbor, MI, USA). VPC-23019 and W146 were from 
Avanti Polar Lipids Inc. (Alabaster, AL, USA). SC-236 was obtained 
from Merck (Darmstadt, Germany).
Cell culture and stimulation
Rat and mouse glomerular mesangial cells were isolated, cultivated 
and characterized as previously described (Pfeilschifter and Vosbeck, 
1991; Hofmann et al., 2008). For experiments in this study, rat mesan-
gial cells between passages 13–18 and mouse mesangial cells between 
passages 8–12 were seeded in 60-mm-diameter dishes and used after 
reaching confluence. Prior stimulation, rat mesangial cells were pre-
incubated with Dulbecco’s modified Eagle medium (DMEM) con-
taining 0.1 mg/ml of fatty acid-free bovine serum albumin. Mouse 
mesangial cells were pre-incubated with DMEM containing 0.1 mg/ml 
of fatty acid-free bovine and 1% fetal bovine serum (Merck, Darmstadt, 
Germany). After 24 h, mesangial cells were stimulated with the indi-
cated substances. Control cells were treated with vehicle alone. Final 
solvent concentration did not exceed 0.2% (v/v).
Two-step polymerase chain reaction (PCR) analysis
Two-step PCR analysis was performed as described (Koch et  al., 
2012). Briefly, 1.2 μg of total RNA was isolated with TRIZOL™ 
reagent (Sigma-Aldrich, Steinheim, Germany) according to the 
manufacturer’s protocol and used for reverse transcriptase poly-
merase chain reaction (RT-PCR; RevertAid™ first strand cDNA syn-
thesis kit, Thermo Fisher Scientific, Waltham, MA, USA) utilizing 
an oligo (dT) primer for amplification. Real-time PCR (TaqMan®) 
was performed using the Applied Biosystems 7500 Fast Real-Time 
PCR System. The TaqMan system, all probes, primers, the reporter 
dyes 6-FAM and VIC, and the software were from Life Technolo-
gies (Darmstadt, Germany). The following TaqMan® assays were 
used: rat S1P1, Rn00568869_m1; rat S1P2, Rn00567877_m1; rat S1P3, 
Rn02758880_s1; rat S1P4, Rn01408085_s1; rat S1P5, Rn01486962_g1; 
mouse S1P1, Mm00514644_m1. The cycling conditions were as fol-
lows: 95°C for 15 min (1 cycle), 95°C for 15 s and 60°C for 1 min (40 
cycles). The threshold cycle (Ct) was calculated by the instrument’s 
software (7500 Fast System SDS Software version 1.4). Analysis 
of the relative mRNA expression was performed using the ΔΔCt 
method. Eukaryotic 18S ribosomal RNA (Life Technologies, Darm-
stadt, Germany) was used for  normalization.
Western blot analysis
Following stimulation the medium was removed and the cells were 
washed once with phosphate-buffered saline (PBS) solution. Thereaf-
ter, cells were scraped into ice-cold lysis buffer (50 mm Tris-HCl, pH 7.4, 
150 mm NaCl, 10% glycerol, 1% Triton X-100, 2 mm ethylenediamine-
tetraacetic acid (EDTA), 2 mm ethylene glycol-bis(β-aminoethyl ether)-
N,N,N′,N′,-tetraacetic acid (EGTA), 40 mm β-glycerophosphate, 50 mm 
sodiumfluoride, 10 μg/ml leupeptin, 10 μg/ml pepstatin A, 1  mm 
phenylmethyl sulfonyl fluoride) and homogenized by sonication. The 
samples were then centrifuged for 10 min at 16,200 g and the super-
natant was taken for protein determination. Cell lysates containing 
equal amounts of protein (50 μg) were separated on sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (10% acrylamide gel) and 
transferred to a nitrocellulose membrane and subjected to Western 
blot analysis as described previously (Huwiler et al., 1995). The S1P1 
antibody was from ProSci Inc. (Poway, USA). The S1P1 antibody speci-
ficity was confirmed using a corresponding blocking peptide (ProSci 
Inc., Poway, USA) exactly as described (Koch et al., 2013b). The S1P3 
antibody was obtained from Cayman Chemicals (Ann Arbor, MI, USA). 
The β-actin antibody was purchased from Santa Cruz ( Heidelberg, 
 Germany). S1P1 and S1P3 antibodies were used at dilutions of 1:1000 
and the β-actin antibody was used at a dilution of 1:3000.
Cell migration assay
Rat mesangial cell migration was measured using a Boyden chamber 
assay exactly as described (Klawitter et al., 2007). Shortly, mesan-
gial cell migration was measured as the ability of cells to migrate 
through a Transwell filter (6.5 mm diameter, 8 mm pore size). After 
serum starvation, cells were detached by trypsinization and seeded 
into Transwell filters at 1 × 105 cells in 100  ml starvation medium 
with or without the indicated stimuli; 500 ml of starvation medium 
were placed in the lower compartment, and the cells were left to 
migrate for the indicated time periods. After treatment, the medium 
was removed and the non-migrating cells were removed from the 
filter by wiping the filter with a cotton pad. The filters were washed 
twice with PBS, fixed in 4% formaldehyde in PBS for 30 min at room 
temperature and again washed in water and methanol. Thereafter, 
the cells were stained with 40,6-diamidino-2-phenylindole (DAPI; 
1 mg/ml) for 15 min at 37°C, washed with methanol and dried. Cells 
that had migrated into the pores of the filters were counted using 
fluorescence microscopy.
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Animal experiments
All animal experiments were conducted in accordance with the Ger-
man Animal Protection Law and were approved by the Ethics Review 
Committee of the District Governments of Darmstadt, Germany. Ani-
mal experiments were performed exactly as described (Förster et al., 
2010). Briefly, male C57BL/6 mice, 8 weeks old, were intraperitoneal 
injected with dexamethasone (10 mg/kg body weight) dissolved in 
PBS. Control animals were injected with 150 ml of PBS. After 24 h, 
kidneys (n = 5 per group) were harvested and taken for isolation of 
glomeruli by using a differential sieving method.
Statistical analysis
All data were statistically analyzed by one-way analysis of variance 
followed by Bonferroni’s post hoc test for multiple comparisons or 
by Student’s t-test for unpaired analysis (GraphPad Prism version 5; 
GraphPad Software, San Diego, CA, USA). Differences with p < 0.05 
were considered to be significant.
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